Maximum Dose of Liothyronine (T3)
The maximum dose of liothyronine is 50 mcg per day for adults. 1
Dosing Considerations
Standard Dosing
- For patients requiring liothyronine as part of combination therapy with levothyroxine, the typical starting dose is 2.5-7.5 mcg once or twice daily 1
- When initiating liothyronine, it's common practice to reduce the levothyroxine dose by 25 mcg/day and add the liothyronine 1
- The recommended ratio of levothyroxine to liothyronine in combination therapy is approximately 13:1 to 20:1 2
Special Populations
- For children, the maximum dose is 15-20 mcg/kg/day (not to exceed 1.0 g/day) 3
- Elderly patients and those with cardiovascular disease require more cautious dosing, similar to levothyroxine dosing principles 4
Monitoring and Titration
- After initiating therapy, TSH and free T4 should be measured after 6-8 weeks to assess response 4
- The goal of combination therapy should be to achieve a physiological ratio of free T3/free T4 without suppressing TSH 2
- Transient episodes of elevated T3 levels with standard doses are unlikely to exceed the reference range and have not been associated with adverse drug reactions 1
Safety Considerations
Potential Adverse Effects
- Excessive doses can lead to thyrotoxicosis with symptoms including headache, nausea, vomiting, and eventually confusion 5
- Unlike classic thyroid storm, T3 overdose may initially present without the expected clinical features of hyperpyrexia, tachycardia, and hypertension 5
- Severe overdose (such as 1000-fold dosing errors) has been reported to cause severe thyrotoxicosis requiring plasmapheresis 5
Risk Mitigation
- Careful dose titration is essential to avoid iatrogenic hyperthyroidism 6
- Patients with atrial fibrillation, cardiac disease, or other serious medical conditions require more frequent monitoring when initiating or adjusting liothyronine therapy 6
- Patients with subclinical hyperthyroidism (TSH <0.1 mIU/L) should have their dose reduced to avoid complications including bone loss and increased fracture risk 6
Clinical Applications
- Liothyronine may be considered for patients who remain symptomatic on levothyroxine monotherapy despite normalized TSH levels 1
- Patients with documented polymorphism of the deiodinase 2 (D2) genes may particularly benefit from the addition of liothyronine 2
- Long-term observational studies (mean follow-up ~9 years) have not shown increased mortality or morbidity risk due to cardiovascular disease, atrial fibrillation, or fractures in patients taking combination therapy compared to levothyroxine monotherapy 1
Remember that liothyronine has a shorter half-life than levothyroxine, which may lead to fluctuations in serum T3 levels throughout the day when using standard formulations 2.